Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M

Archives of Internal Medicine

Volumn 158, Issue 13, 1998, Pages 1434-1439

  Kovanen, Petri T ^a   Mänttäri, Matti ^b   Palosuo, Timo ^c   Manninen, Vesa ^b   Aho, Kimmo ^c  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; TRIACYLGLYCEROL;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; DYSLIPIDEMIA; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; HUMANS; HYPERLIPIDEMIAS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; RISK; RISK FACTORS;

EID: 2642611980     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.13.1434     Document Type: Article

References (47)

1. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
2. Lopes-Virella MF, Virella G. Atherosclerosis and autoimmunity. Clin Immunol Immunopathol. 1994;73:155-167.
3. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27-33.
4. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
5. Buja LM, Willerson JT. Role of inflammation in coronary plaque disruption. Circulation. 1994;89:503-505.
6. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
7. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the ECAT Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995; 332:635-641.
8. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
9. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
10. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
11. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989;135:169-175.
12. Kaartinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cell in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 1994;90:1669-1678.
13. Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
14. Tertov W, Orekhov AN, Kacharava AG, Sobenin IA, Perova NV, Smirnov VN. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol. 1990;52:300-308.
15. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation. 1995;91:2125-2131.
16. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995;91:1084-1088.
17. Wilcox JN. Thrombotic mechanisms in atherosclerosis. Coron Artery Dis. 1994; 5:223-229.
18. Baker WF Jr, Bick RL. Antiphospholipid antibodies in coronary artery disease: a review. Semin Thromb Hemost. 1994;20:27-45.
19. Vaarala O, Mänttäri M, Manninen V, et al. Anti-cardiolipid antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23-27.
20. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273-278.
21. Nieminen MS, Mattila K, Valtonen V. Infection and inflammation as risk factors for myocardial infarction. Eur Heart J. 1993;14(suppl K):12-16.
22. Muscari A, Bozzoli C, Gerratana C, et al. Association of serum IgA and C4 with severe atherosclerosis. Atherosclerosis. 1988;74:179-186.
23. Criqui MH, Lee ER, Hamburger RN, Klauber MR, Coughlin SS. IgE and cardiovascular disease: results from a population-based study. Am J Med. 1987;82:964-968.
24. Brinkschmidt T, Heuck CG. Schlierf G, Buchholz L, Schmidt-Gayk H. The association of hyperlipoproteinemia with dysimmunoglobulinemia. Atherosclerosis. 1986;59:323-328.
25. Erbringer A, Doyle AE. Raised serum IgG levels in hypertension. BMJ. 1970;2: 146-148.
26. Martinez-Amenos A, Buendia E, Carreras L, et al. Humoral and cellular immunological abnormalities in hypertensive patients. J Clin Hypertens. 1985;1:153-160.
27. Gulsvik A, Fagerhol MK. Smoking and immunoglobulin levels. Lancet 1979;1:449.
28. Andersen P, Pedersen OF, Bach B, Bonde GJ. Serum antibodies and immunoglobulins in smokers and nonsmokers. Clin Exp Immunol. 1982;47:467-473.
29. Bahna SL, Heiner DC, Myhre BA. Immunoglobulin E pattern in cigarette smokers. Allergy. 1983;38:57-64.
30. Langer RD, Criqui MH, Feigelson HS, McCann TJ, Hamburger RN. IgE predicts future nonfatal myocardial infarction in men. J Clin Epidemiol. 1996;49:203-209.
31. Muscari A, Bozzoli C, Puddu GM, et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med. 1995;98:357-364.
32. Frick MH, Elo O, Haapa K, et al. The Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
33. Mänttäri M, Elo O, Frick MH, et al. The Helsinki Heart Study: basic design and randomization procedure. Eur Heart J. 1987;8(suppl 1):1-29.
34. Frick MH, Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Mänttäri M. HDL-cholesterol as a risk factor in coronary heart disease: an update of the Helsinki Heart Study. Drugs. 1990;40(suppl 1):7-14.
35. Puurunen M, Mänttäri M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154: 2605-2609.
36. Poston RN, Davies DF. Immunity and inflammation in the pathogenesis of atherosclerosis. Atherosclerosis. 1974;19:353-367.
37. Minick CR, Murphy GE. Experimental induction of atheroarteriosclerosis by the synergy of allergic injury to arteries and lipid-rich diet, II: effect of repeatedly injected foreign protein in rabbits fed a lipid-rich, cholesterol-poor diet. Am J Pathol. 1973;73:265-300.
38. Howard AN, Patelski J, Bowyer DE, Gresham GA. Atherosclerosis induced in hypocholesterolaemic baboons by immunological injury and the effects of i/v polyunsaturated phosphatidyl choline. Atherosclerosis. 1971;14:17-29.
39. Sutton BJ, Gouid HJ. The human IgE network. Nature. 1993;366:421-428.
40. Joseph M, Capron A, Ameisen J-C, et al. The receptor for IgE on blood platelets. Eur J Immunol. 1986;16:306-312.
41. Ishizaka T, Ishizaka K. Activation of mast cells for mediator release through IgE receptors. Prog Allergy. 1984;34:188-235.
42. Ma H, Kovanen PT. IgE-dependent generation of foam cells: an immune mechanism involving degranulation of sensitized mast cells with resultant uptake of LDL by macrophages. Arterioscler Thromb Vase Biol. 1995;15:811-819.
43. Kaartinen M, Penttilä A, Kovanen PT. Extracellular mast cell granules carry apolipoprotein B-100-containing lipoproteins into phagocytes in human arterial intima: functional coupling of exocytosis and phagocytosis in neighboring cells. Arterioscler Thromb Vase Biol. 1995;15:2047-2054.
44. Ginsburg R, Bristow MR, Davis K, Dibiase A, Billingham ME. Quantitative pharmacologic responses of normal and atherosclerotic isolated human epicardial coronary arteries. Circulation. 1984;69:430-440.
45. Gruber BL, Marchese MJ, Suzuki K, et al. Synovial procollagenase activation by human mast cell tryptase: dependence upon matrix metalloproteinase 3 activation. J Clin Invest. 1989;84:1657-1662.
46. Saarinen J, Kalkkinen N, Welgus HG, Kovanen PT. Activation of human interstitial procollagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. J Biol Chem. 1994;269:18134-18140.
47. Kaartinen M, Penttilä A, Kovanen PT. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-α. Circulation. 1996;94:2787-2792.